NP Theresa Stukus and NP Nelli Zafman discuss long-term management considerations for a patient with metastatic triple-negative breast cancer (mTNBC) who is experiencing ongoing treatment-related toxicities while maintaining disease control on frontline therapy.
NP Theresa Stukus and NP Nelli Zafman discuss how the distinct toxicity profiles of available antibody-drug conjugates (ADCs) influence supportive care strategies for patients with metastatic triple-negative breast cancer (mTNBC).
NP Theresa Stukus and NP Nelli Zafman discuss proactive strategies for preventing and managing oral toxicities associated with antibody-drug conjugate (ADC) therapy in patients with metastatic triple-negative breast cancer (mTNBC).
NP Theresa Stukus and NP Nelli Zafman discuss practical strategies for preventing and managing neutropenia in patients with metastatic triple-negative breast cancer (mTNBC) receiving antibody-drug conjugate (ADC) therapy.
NP Theresa Stukus and NP Nelli Zafman discuss the importance of proactive patient education to support early recognition and management of gastrointestinal toxicities in metastatic triple-negative breast cancer (mTNBC).
NP Theresa Stukus and NP Nelli Zafman introduce the second clinical scenario, focusing on the evaluation and management of new-onset diarrhea in a patient with metastatic triple-negative breast cancer (mTNBC) receiving sacituzumab govitecan in combination with an immune checkpoint inhibitor.
NP Theresa Stukus and NP Nelli Zafman discuss the unique challenges of caring for younger patients with metastatic triple-negative breast cancer (mTNBC), emphasizing that treatment planning extends beyond disease management to encompass the patient's personal, family, and professional responsibilities.
NP Theresa Stukus and NP Nelli Zafman discuss how differences among available frontline antibody-drug conjugates (ADCs) can be used to individualize treatment for patients with metastatic triple-negative breast cancer (mTNBC).
NP Theresa Stukus and NP Nelli Zafman discuss key considerations when interpreting emerging frontline clinical trial data for antibody-drug conjugates (ADCs) in metastatic triple-negative breast cancer (mTNBC).
NP Theresa Stukus and NP Nelli Zafman discuss how recent advances in frontline antibody-drug conjugate (ADC) therapy are enabling a more individualized approach to the management of metastatic triple-negative breast cancer (mTNBC).
NP Theresa Stukus and NP Nelli Zafman introduce the first clinical scenario featuring a young woman with newly diagnosed metastatic triple-negative breast cancer (mTNBC) and discuss the clinical and personal factors that influence frontline treatment selection.
NP Theresa Stukus and NP Nelli Zafman discuss the expanding role of oncology nurse practitioners and advanced practice providers in delivering comprehensive care for patients with metastatic triple-negative breast cancer (mTNBC).
NP Theresa Stukus and NP Nelli Zafman discuss the essential role of comprehensive biomarker testing in guiding individualized treatment decisions for patients with metastatic triple-negative breast cancer (mTNBC).
NP Theresa Stukus and NP Nelli Zafman discuss how recent clinical trial data, updated clinical practice guidelines, and new FDA approvals are influencing frontline treatment decisions for metastatic triple-negative breast cancer (mTNBC).
Why first-line choices matter in metastatic TNBC: many miss second-line care, and new antibody-drug conjugates boost survival over chemo.
Oncology NPs discuss new frontline options for metastatic triple-negative breast cancer, using cases to guide therapy choice and manage toxicities.
